Merck + Co., Inc.

Albert J Robichaud

Sander G Mills

Malcolm MacCoss

Paul E Finke

Jeffrey John Hale

Charles G Caldwell

Yuan-Ching P Chiang

Laura C Meurer

Philippe L Durette

Shrenik K Shah

Conrad P Dorn

Ping Chen

Ihor E Kopka

Edward M Scolnick

Gregory D Berger

Daniel J Miller

Robert W Marquis, Jr

Edward Holson

The present invention is directed to certain novel compounds represented by structural formula I: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, m, n and the dashed lines are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.

Phenyl spiroethercycloalkyl tachykinin receptor antagonists

The present invention is directed to certain novel compounds represented by structural formula I: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, A, Q, W, X, Y, Z and n are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.

Cycloalkyl tachykinin receptor antagonists

Disclosed are substituted aryl piperazines of Formula I ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis. In particular compounds of Formula I are shown to be neurokinin antagonists.

Substituted aryl piperazines as neurokinin antagonists

Disclosed herein are compounds of structural formula (I) ##STR1## which are useful as cholesterol lowering agents. These compounds are also useful as inhibitors of squalene synthase, inhibitors of fungal growth, inhibitors of farnesyl-protein transferase and farnesylation of the oncogene protein Ras. These compounds are also useful in the treatment of cancer.

Cholesterol lowering compounds

Growing community of inventors

Stirling, NJ, United States of America

Albert J Robichaud